Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 studyFranco Locatelli, Cristina Díaz de Heredia, Bülent Antmen et al.|The Lancet Haematology|2024Cited by 18
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to <100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPANDPaola Guglielmelli, Heinz Gisslinger, Haitao Meng et al.|Therapeutic Advances in Hematology|2022Cited by 11